Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Cyclooxygenase 2 inhibitors: discovery, selectivity and the future
Autore:
Marnett, LJ; Kalgutkar, AS;
Indirizzi:
Vanderbilt Univ, Sch Med, Mem Lab Canc Res,Dept Biochem, Ctr Mol Toxicol, Nashville, TN 37232 USA Vanderbilt Univ Nashville TN USA 37232 l Toxicol, Nashville, TN 37232 USA Vanderbilt Univ, Sch Med, Mem Lab Canc Res,Dept Chem, Ctr Mol Toxicol, Nashville, TN 37232 USA Vanderbilt Univ Nashville TN USA 37232 l Toxicol, Nashville, TN 37232 USA Vanderbilt Univ, Sch Med, Vanderbilt Canc Ctr, Nashville, TN 37232 USA Vanderbilt Univ Nashville TN USA 37232 Canc Ctr, Nashville, TN 37232 USA
Titolo Testata:
TRENDS IN PHARMACOLOGICAL SCIENCES
fascicolo: 11, volume: 20, anno: 1999,
pagine: 465 - 469
Fonte:
ISI
Lingua:
ENG
Soggetto:
PROSTAGLANDIN G/H SYNTHASE-1; TIME-DEPENDENT INHIBITION; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; COLON-CANCER; CRYSTAL-STRUCTURE; PHORBOL ESTER; H-2 SYNTHASE; ACTIVE-SITE; H SYNTHASES; ASPIRIN;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
52
Recensione:
Indirizzi per estratti:
Indirizzo: Marnett, LJ Vanderbilt Univ, Sch Med, Mem Lab Canc Res,Dept Biochem, Ctr Mol Toxicol, 221 Kirkland Hall, Nashville, TN 37232 USA Vanderbilt Univ 221 Kirkland Hall Nashville TN USA 37232 2 USA
Citazione:
L.J. Marnett e A.S. Kalgutkar, "Cyclooxygenase 2 inhibitors: discovery, selectivity and the future", TRENDS PHAR, 20(11), 1999, pp. 465-469

Abstract

The recent marketing of two selective cyclooxygenase 2 (COX-2) inhibitors climaxes the first phase of an exciting and fast-paced effort to exploit a novel molecular target for nonsteroidal anti-inflammatory drugs (NSAIDs). Much has been written in the lay and scientific press about the potential ofCOX-2 inhibitors as anti-inflammatory and analgesic agents that lack the gastrointestinal side-effects of traditional NSAIDs. Although research on COX-2 inhibitors has focussed mainly on inflammation and pain, experimental and epidemiological data suggest that COX-2 inhibitors could be used in the treatment or prevention of a broader range of diseases. In this review, some key points and unresolved issues related to the discovery of COX-2 inhibitors, the kinetic and structural basis for their selectivity, and possible complications in their development and use will be discussed.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 13/07/20 alle ore 03:02:08